Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.685 USD | -0.07% | +10.45% | -33.69% |
15/05 | GRIFOLS : In line Q1 and on track deleveraging; worth a go | |
14/05 | Grifols, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company appears to be poorly valued given its net asset value.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.69% | 6.63B | - | ||
+0.10% | 91.42B | A- | ||
+3.16% | 41.08B | A- | ||
-11.53% | 34.26B | B- | ||
+53.99% | 25.27B | A | ||
-9.44% | 12.81B | B- | ||
-12.25% | 11.6B | D+ | ||
-44.00% | 11.42B | B | ||
+5.77% | 9.16B | B+ | ||
-6.90% | 8.22B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GRF Stock
- GRFS Stock
- Ratings Grifols, S.A.